亚胺培南-西司他丁诱发癫痫发作:病例报告

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Current drug safety Pub Date : 2024-10-07 DOI:10.2174/0115748863324094240919114700
Ghaith Aloui, Baraa Ben Houria, Mohamed Ali Yousfi
{"title":"亚胺培南-西司他丁诱发癫痫发作:病例报告","authors":"Ghaith Aloui, Baraa Ben Houria, Mohamed Ali Yousfi","doi":"10.2174/0115748863324094240919114700","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Imipenem-cilastatin, a carbapenem antibiotic, is commonly used for severe bacterial infections. While generally well-tolerated, it can rarely cause central nervous system toxicity, including seizures. We have, herein, reported a case of imipenem-cilastatin-induced seizure in a 20-year-old patient.</p><p><strong>Case presentation: </strong>A 20-year-old male was admitted to the intensive care unit for febrile status epilepticus and acute respiratory distress syndrome. Initial evaluations ruled out underlying causes and anti-epileptic treatment has been initiated. Despite having an effective anti-epileptic treatment for three months of hospitalization, seizure recurrence occurred, leading to antibiotic regimen adjustment as the imputability of imipenem-cilastatin was suspected. After discontinuation of the involved drug, the patient remained neurologically stable. Previous literature has reported cases of imipenem-cilastatin-induced seizures, particularly in elderly patients or at higher dosages. The causality assessment was conducted using the updated French method, which rated the chronological criterion as C2 and the semiological criterion as S2. The intrinsic imputability score was I3, indicating plausible causality, and the extrinsic bibliographic score was B3.</p><p><strong>Conclusion: </strong>Our case has highlighted the importance of promptly recognizing imipenem-cilastatin- induced epileptic seizures in order to treat them more effectively and thus optimize the patient's care. Therefore, we emphasize that clinicians be vigilant about the side effects of its use, particularly in patients with neurological susceptibilities. We also advocate a personalized choice of antibiotics, taking into account both antimicrobial efficacy and potential adverse effects, for better outcomes with fewer risks.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imipenem-Cilastatin-Induced Seizures: A Case Report.\",\"authors\":\"Ghaith Aloui, Baraa Ben Houria, Mohamed Ali Yousfi\",\"doi\":\"10.2174/0115748863324094240919114700\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Imipenem-cilastatin, a carbapenem antibiotic, is commonly used for severe bacterial infections. While generally well-tolerated, it can rarely cause central nervous system toxicity, including seizures. We have, herein, reported a case of imipenem-cilastatin-induced seizure in a 20-year-old patient.</p><p><strong>Case presentation: </strong>A 20-year-old male was admitted to the intensive care unit for febrile status epilepticus and acute respiratory distress syndrome. Initial evaluations ruled out underlying causes and anti-epileptic treatment has been initiated. Despite having an effective anti-epileptic treatment for three months of hospitalization, seizure recurrence occurred, leading to antibiotic regimen adjustment as the imputability of imipenem-cilastatin was suspected. After discontinuation of the involved drug, the patient remained neurologically stable. Previous literature has reported cases of imipenem-cilastatin-induced seizures, particularly in elderly patients or at higher dosages. The causality assessment was conducted using the updated French method, which rated the chronological criterion as C2 and the semiological criterion as S2. The intrinsic imputability score was I3, indicating plausible causality, and the extrinsic bibliographic score was B3.</p><p><strong>Conclusion: </strong>Our case has highlighted the importance of promptly recognizing imipenem-cilastatin- induced epileptic seizures in order to treat them more effectively and thus optimize the patient's care. Therefore, we emphasize that clinicians be vigilant about the side effects of its use, particularly in patients with neurological susceptibilities. We also advocate a personalized choice of antibiotics, taking into account both antimicrobial efficacy and potential adverse effects, for better outcomes with fewer risks.</p>\",\"PeriodicalId\":10777,\"journal\":{\"name\":\"Current drug safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748863324094240919114700\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863324094240919114700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:亚胺培南-西司他丁是一种碳青霉烯类抗生素,常用于治疗严重的细菌感染。虽然亚胺培南-西司他丁一般耐受性良好,但很少会引起中枢神经系统毒性,包括癫痫发作。我们在此报告了一例亚胺培南-西司他丁诱发癫痫发作的病例,患者年仅 20 岁:一名 20 岁的男性因发热性癫痫和急性呼吸窘迫综合征被送入重症监护室。初步评估排除了潜在病因,并开始了抗癫痫治疗。尽管在住院的三个月里进行了有效的抗癫痫治疗,但癫痫再次发作,导致抗生素方案调整,因为怀疑亚胺培南-西司他丁无效。停用相关药物后,患者的神经系统仍然稳定。以前的文献曾报道过亚胺培南-西司他丁诱发癫痫发作的病例,尤其是老年患者或剂量较大的患者。因果关系评估采用了最新的法国方法,将年代学标准评为 C2,将符号学标准评为 S2。内在可归责性评分为 I3,表明因果关系可信,外在文献评分为 B3:我们的病例强调了及时识别亚胺培南-西司他丁诱发的癫痫发作的重要性,以便更有效地治疗癫痫发作,从而优化患者的护理。因此,我们强调临床医生应警惕使用亚胺培南-西司他丁的副作用,尤其是对神经系统敏感的患者。我们还提倡个性化选择抗生素,同时考虑抗菌效果和潜在的不良反应,以便在降低风险的同时获得更好的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Imipenem-Cilastatin-Induced Seizures: A Case Report.

Background: Imipenem-cilastatin, a carbapenem antibiotic, is commonly used for severe bacterial infections. While generally well-tolerated, it can rarely cause central nervous system toxicity, including seizures. We have, herein, reported a case of imipenem-cilastatin-induced seizure in a 20-year-old patient.

Case presentation: A 20-year-old male was admitted to the intensive care unit for febrile status epilepticus and acute respiratory distress syndrome. Initial evaluations ruled out underlying causes and anti-epileptic treatment has been initiated. Despite having an effective anti-epileptic treatment for three months of hospitalization, seizure recurrence occurred, leading to antibiotic regimen adjustment as the imputability of imipenem-cilastatin was suspected. After discontinuation of the involved drug, the patient remained neurologically stable. Previous literature has reported cases of imipenem-cilastatin-induced seizures, particularly in elderly patients or at higher dosages. The causality assessment was conducted using the updated French method, which rated the chronological criterion as C2 and the semiological criterion as S2. The intrinsic imputability score was I3, indicating plausible causality, and the extrinsic bibliographic score was B3.

Conclusion: Our case has highlighted the importance of promptly recognizing imipenem-cilastatin- induced epileptic seizures in order to treat them more effectively and thus optimize the patient's care. Therefore, we emphasize that clinicians be vigilant about the side effects of its use, particularly in patients with neurological susceptibilities. We also advocate a personalized choice of antibiotics, taking into account both antimicrobial efficacy and potential adverse effects, for better outcomes with fewer risks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
期刊最新文献
Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature. Facial Hyperpigmentation Following Adalimumab. Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review. A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020. A Review of Published Cases Regarding the Amphotericin B Deoxycholate Overdose in the Pediatric Population and a Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1